{"id":"NCT01600716","sponsor":"Allergan","briefTitle":"Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06-13","primaryCompletion":"2014-04-04","completion":"2015-03-27","firstPosted":"2012-05-17","resultsPosted":"2016-03-22","lastUpdate":"2019-04-30"},"enrollment":144,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Urinary Incontinence","Multiple Sclerosis","Neurogenic Bladder"],"interventions":[{"type":"BIOLOGICAL","name":"OnabotulinumtoxinA","otherNames":["BOTOX®","botulinum toxin Type A"]},{"type":"DRUG","name":"Placebo (Normal Saline)","otherNames":[]}],"arms":[{"label":"OnabotulinumtoxinA","type":"EXPERIMENTAL"},{"label":"Placebo (Normal Saline)","type":"OTHER"}],"summary":"This study will evaluate the safety and efficacy of OnabotulinumtoxinA (BOTOX®) for the treatment of urinary incontinence due to NDO in non-catheterizing patients with MS.","primaryOutcome":{"measure":"Change From Baseline in Daily Average Frequency of Urinary Incontinence Episodes","timeFrame":"Baseline, Week 6","effectByArm":[{"arm":"OnabotulinumtoxinA","deltaMin":4.18,"sd":3.167},{"arm":"Placebo (Normal Saline)","deltaMin":4.32,"sd":2.422}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":10,"countries":["United States","Belgium","Canada","Czechia","France","Poland","Portugal","Russia"]},"refs":{"pmids":["30030330"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":66},"commonTop":["Urinary tract infection","Urinary Retention","Bacteriuria","Residual Urine Volume","Leukocyturia"]}}